We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

31 hedge funds and large institutions have $2.83M invested in PDS Biotechnology in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.15% less ownership

Funds ownership: 1.56% → 1.41% (-0.15%)

16% less funds holding

Funds holding: 37 → 31 (-6)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

65% less capital invested

Capital invested by funds: $8.01M → $2.83M (-$5.18M)

Holders
31
Holders Change
-6
Holders Change %
-16.22%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
6
Closed
11
Calls
$15K
Puts
–
Net Calls
+$15K
Net Calls Change
+$15K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$200K
2
AFM
Anson Funds Management
Texas
+$161K
3
WAM
Wealthspire Advisors (Maryland)
Maryland
+$66.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$52.7K
5
Citadel Advisors
Citadel Advisors
Florida
+$40K

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$820K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$339K
3
Goldman Sachs
Goldman Sachs
New York
-$88K
4
AAMU
Amundi Asset Management US
Massachusetts
-$64K
5
Millennium Management
Millennium Management
New York
-$52K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$916K – – –
NLVP
2
New Leaf Venture Partners
New York
$753K – – –
D.E. Shaw & Co
3
D.E. Shaw & Co
New York
$238K -$10.6K -798 -2%
Renaissance Technologies
4
Renaissance Technologies
New York
$181K +$200K +15,081 +114%
Vanguard Group
5
Vanguard Group
Pennsylvania
$112K -$339K -25,602 -59%
BlackRock
6
BlackRock
New York
$109K -$252 -19 -0.1%
AFM
7
Anson Funds Management
Texas
$78K +$161K +12,171 New
Two Sigma Investments
8
Two Sigma Investments
New York
$76K -$20.2K -1,527 -11%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$75K – – –
SB
10
Samsara BioCapital
California
$59K +$121K +9,167 New
RJFSA
11
Raymond James Financial Services Advisors
Florida
$51K – – –
WAM
12
Wealthspire Advisors (Maryland)
Maryland
$32K +$66.2K +5,000 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$31K +$52.7K +3,983 +512%
RC
14
RegentAtlantic Capital
New Jersey
$22K – – –
Two Sigma Advisers
15
Two Sigma Advisers
New York
$20K -$265 -20 -0.6%
Citadel Advisors
16
Citadel Advisors
Florida
$19K +$40K +3,020 New
PAM
17
Panagora Asset Management
Massachusetts
$17K +$12K +905 +52%
Northern Trust
18
Northern Trust
Illinois
$14K – – –
TSS
19
Two Sigma Securities
New York
$8K +$16.2K +1,222 New
BFM
20
Boothbay Fund Management
New York
$6K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$5K – – –
State Street
22
State Street
Massachusetts
$4K – – –
Creative Planning
23
Creative Planning
Kansas
$3K – – –
PNC Financial Services Group
24
PNC Financial Services Group
Pennsylvania
$2K – – –
IA
25
IFP Advisors
Florida
$1K – – –
1
2

PDSB Hedge Fund Activity: Q4 2018 in Review

31 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2018, worth a combined $2.83M — down 65% from $8.01M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PDSB and 5 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $200K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $820K sold.

  • 31 institutional investors held PDS Biotechnology (PDSB) as of Q4 2018, down from 37 in Q3 2018.
  • Funds reported $2.83M of PDS Biotechnology stock for Q4 2018, down 65% quarter-over-quarter.
  • 5 funds opened new PDS Biotechnology positions in Q4 2018 and 11 closed out, a net change of -6 holders.
  • The largest PDS Biotechnology buyer in Q4 2018 was Renaissance Technologies, an estimated $200K added.
  • The largest PDS Biotechnology seller in Q4 2018 was Ghost Tree Capital, an estimated $820K sold.

Based on aggregated 13F filings for Q4 2018.